Last reviewed · How we verify
Adjuvanted RSVPreF3 vaccine
RSVPreF3 is a recombinant respiratory syncytial virus (RSV) fusion (F) protein vaccine designed to elicit protective immune responses against RSV infection.
RSVPreF3 is a recombinant respiratory syncytial virus (RSV) fusion (F) protein vaccine designed to elicit protective immune responses against RSV infection. Used for Prevention of respiratory syncytial virus (RSV) disease in adults.
At a glance
| Generic name | Adjuvanted RSVPreF3 vaccine |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Recombinant protein vaccine |
| Target | RSV fusion (F) protein, prefusion conformation |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 2 |
Mechanism of action
The vaccine contains a prefusion-stabilized form of the RSV F protein (PreF3), which is a key surface antigen that triggers neutralizing antibodies and cellular immunity. The adjuvant component enhances the immunogenicity of the vaccine by activating innate immune responses. This combination aims to provide robust protection against RSV disease, particularly in older adults and other high-risk populations.
Approved indications
- Prevention of respiratory syncytial virus (RSV) disease in adults
Common side effects
- Injection site pain
- Injection site erythema
- Fatigue
- Myalgia
- Headache
Key clinical trials
- A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant (PHASE2)
- Immunogenicity of RSVPreF3 Vaccine in Immunocompromised Persons (PHASE2)
- RSV Immunogenicity Study in the Elderly (RISE) (PHASE3)
- A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone or Co-administered With an Adjuvanted Vaccine Against Influenza in Adults Aged 65 Years and Above (PHASE3)
- Extension Study to Evaluate the Safety and Immunogenicity of a Revaccination Dose of the RSVPreF3 OA Investigational Vaccine in Adults 60 Years and Older Who Participated in the RSV OA=ADJ-002 Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Adjuvanted RSVPreF3 vaccine CI brief — competitive landscape report
- Adjuvanted RSVPreF3 vaccine updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI